Free Trial

Myriad Genetics (MYGN) Financials

Myriad Genetics logo
$8.01 -0.07 (-0.87%)
Closing price 04:00 PM Eastern
Extended Trading
$8.02 +0.01 (+0.06%)
As of 04:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Myriad Genetics

Annual Income Statements for Myriad Genetics

This table shows Myriad Genetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-112 -263 -127
Consolidated Net Income / (Loss)
-112 -263 -127
Net Income / (Loss) Continuing Operations
-112 -263 -127
Total Pre-Tax Income
-141 -262 -124
Total Operating Income
-141 -257 -124
Total Gross Profit
476 517 585
Total Revenue
678 753 838
Operating Revenue
678 753 838
Total Cost of Revenue
202 236 252
Operating Cost of Revenue
202 236 252
Total Operating Expenses
617 774 709
Selling, General & Admin Expense
248 284 276
Marketing Expense
267 289 284
Research & Development Expense
85 89 113
Other Operating Expenses / (Income)
0.00 113 -21
Impairment Charge
17 0.00 57
Total Other Income / (Expense), net
0.00 -4.80 0.00
Interest Expense
3.20 2.90 2.80
Interest & Investment Income
2.60 2.50 1.70
Other Income / (Expense), net
0.60 -4.40 1.10
Income Tax Expense
-29 1.10 3.80
Basic Earnings per Share
($1.39) ($3.18) ($1.41)
Weighted Average Basic Shares Outstanding
80.60M 82.80M 90.60M
Diluted Earnings per Share
($1.39) ($3.18) ($1.41)
Weighted Average Diluted Shares Outstanding
80.60M 82.80M 90.60M
Weighted Average Basic & Diluted Shares Outstanding
81.22M 89.87M 91.31M

Quarterly Income Statements for Myriad Genetics

This table shows Myriad Genetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-35 -42 -55 -116 -61 -31 -26 -37 -22 -43
Consolidated Net Income / (Loss)
-35 -42 -55 -116 -61 -31 -26 -37 -22 -43
Net Income / (Loss) Continuing Operations
-35 -42 -55 -116 -61 -31 -26 -37 -22 -43
Total Pre-Tax Income
-44 -52 -53 -116 -61 -32 -26 -37 -21 -39
Total Operating Income
-45 -52 -52 -114 -60 -31 -28 -37 -20 -39
Total Gross Profit
106 124 122 126 134 135 138 147 150 151
Total Revenue
156 178 181 184 192 197 202 212 213 211
Operating Revenue
156 178 181 184 192 197 202 212 213 211
Total Cost of Revenue
50 54 59 58 58 62 65 64 64 60
Operating Cost of Revenue
50 54 59 58 58 62 65 64 64 60
Total Operating Expenses
151 176 174 239 194 166 166 184 170 190
Selling, General & Admin Expense
131 -120 152 141 136 -145 141 145 139 -149
Research & Development Expense
21 23 23 21 24 21 25 27 29 33
Total Other Income / (Expense), net
0.80 0.10 -0.40 -2.40 -1.10 -0.90 2.00 -0.70 -1.20 -0.10
Interest Expense
0.80 0.90 0.50 0.50 1.00 0.90 0.50 0.80 0.80 0.70
Interest & Investment Income
1.10 1.00 0.70 0.50 0.60 0.70 0.60 0.40 0.40 0.30
Other Income / (Expense), net
0.50 - -0.60 -2.40 -0.70 -0.70 1.90 -0.30 -0.80 0.30
Income Tax Expense
-9.10 -9.80 2.10 0.00 0.10 -1.10 0.10 -0.50 0.90 3.30
Basic Earnings per Share
($0.43) ($0.52) ($0.67) ($1.42) ($0.75) ($0.34) ($0.29) ($0.41) ($0.24) ($0.47)
Weighted Average Basic Shares Outstanding
80.70M 80.60M 81.30M 81.70M 81.90M 82.80M 89.90M 90.60M 90.90M 90.60M
Diluted Earnings per Share
($0.43) ($0.52) ($0.67) ($1.42) ($0.75) ($0.34) ($0.29) ($0.41) ($0.24) ($0.47)
Weighted Average Diluted Shares Outstanding
80.70M 80.60M 81.30M 81.70M 81.90M 82.80M 89.90M 90.60M 90.90M 90.60M
Weighted Average Basic & Diluted Shares Outstanding
81.03M 81.22M 81.56M 81.88M 82.20M 89.87M 90.51M 90.82M 91.04M 91.31M

Annual Cash Flow Statements for Myriad Genetics

This table details how cash moves in and out of Myriad Genetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents
-192 75 -29
Net Cash From Operating Activities
-106 -111 -8.70
Net Cash From Continuing Operating Activities
-106 -111 -8.70
Net Income / (Loss) Continuing Operations
-112 -263 -127
Consolidated Net Income / (Loss)
-112 -263 -127
Depreciation Expense
53 62 61
Non-Cash Adjustments To Reconcile Net Income
85 65 111
Changes in Operating Assets and Liabilities, net
-132 14 -53
Net Cash From Investing Activities
-78 32 -12
Net Cash From Continuing Investing Activities
-78 32 -12
Purchase of Property, Plant & Equipment
-45 -73 -30
Acquisitions
-57 0.00 0.00
Purchase of Investments
-103 0.00 0.00
Divestitures
0.00 0.00 8.80
Sale and/or Maturity of Investments
128 105 9.00
Net Cash From Financing Activities
-8.00 153 -7.40
Net Cash From Continuing Financing Activities
-8.00 153 -7.40
Repayment of Debt
-0.70 -42 -120
Issuance of Debt
0.00 80 120
Issuance of Common Equity
6.30 124 5.90
Other Financing Activities, net
-14 -9.00 -14
Effect of Exchange Rate Changes
-0.60 0.60 -1.00

Quarterly Cash Flow Statements for Myriad Genetics

This table details how cash moves in and out of Myriad Genetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
4.50 -44 -3.30 50 -28 56 -35 -4.40 8.60 2.10
Net Cash From Operating Activities
-2.80 -7.30 -33 -0.90 -22 -55 -19 2.60 0.70 6.60
Net Cash From Continuing Operating Activities
-2.80 -7.30 -33 -0.90 -22 -55 -19 2.60 0.70 6.60
Net Income / (Loss) Continuing Operations
-35 -42 -55 -116 -61 -31 -26 -37 -22 -43
Consolidated Net Income / (Loss)
-35 -42 -55 -116 -61 -31 -26 -37 -22 -43
Depreciation Expense
13 14 19 13 14 15 16 15 16 15
Non-Cash Adjustments To Reconcile Net Income
21 27 24 19 15 8.00 10 28 15 58
Changes in Operating Assets and Liabilities, net
-1.70 -5.60 -22 83 11 -58 -19 -3.30 -8.20 -23
Net Cash From Investing Activities
11 -36 35 12 -2.50 -12 -7.10 -6.40 7.50 -5.90
Net Cash From Continuing Investing Activities
11 -36 35 12 -2.50 -12 -7.10 -6.40 7.50 -5.90
Purchase of Property, Plant & Equipment
-18 -15 -24 -19 -18 -14 -8.60 -8.90 -6.30 -5.90
Net Cash From Financing Activities
-3.60 -2.10 -4.90 38 -2.50 122 -8.80 2.40 -3.10 2.10
Net Cash From Continuing Financing Activities
-3.60 -2.10 -4.90 38 -2.50 122 -8.80 2.40 -3.10 2.10
Repayment of Debt
-0.70 - 0.00 -1.40 -0.20 -40 -60 -20 -20 -20
Issuance of Debt
- - 0.00 40 - 40 60 20 20 20
Issuance of Common Equity
0.90 2.40 - - - 124 - - - 2.90
Other Financing Activities, net
-3.80 -4.50 -4.90 -0.20 -2.30 -1.60 -8.80 -0.60 -3.10 -1.30
Effect of Exchange Rate Changes
-0.50 0.70 0.20 0.30 -0.60 0.70 -0.80 -0.70 1.20 -0.70

Annual Balance Sheets for Myriad Genetics

This table presents Myriad Genetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets
1,199 1,147 1,028
Total Current Assets
275 314 298
Cash & Equivalents
57 132 102
Short-Term Investments
58 8.80 0.00
Accounts Receivable
102 114 121
Inventories, net
20 22 28
Prepaid Expenses
20 19 31
Current Deferred & Refundable Income Taxes
18 17 16
Plant, Property, & Equipment, net
83 119 117
Total Noncurrent Assets
841 714 612
Goodwill
287 287 286
Intangible Assets
380 350 262
Other Noncurrent Operating Assets
119 77 64
Total Liabilities & Shareholders' Equity
1,199 1,147 1,028
Total Liabilities
313 363 327
Total Current Liabilities
137 156 164
Accounts Payable
29 26 32
Accrued Expenses
94 114 119
Other Current Liabilities
14 16 13
Total Noncurrent Liabilities
176 207 162
Long-Term Debt
0.00 39 40
Noncurrent Deferred & Payable Income Tax Liabilities
27 30 33
Other Noncurrent Operating Liabilities
149 139 90
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
886 783 701
Total Preferred & Common Equity
886 783 701
Total Common Equity
886 783 701
Common Stock
1,261 1,416 1,459
Retained Earnings
-366 -630 -757
Accumulated Other Comprehensive Income / (Loss)
-8.90 -3.70 -0.80

Quarterly Balance Sheets for Myriad Genetics

This table presents Myriad Genetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
1,212 1,169 1,187 1,149 1,111 1,085 1,081
Total Current Assets
352 262 294 265 290 292 293
Cash & Equivalents
111 54 103 76 97 92 100
Short-Term Investments
83 25 19 10 7.40 4.90 0.00
Accounts Receivable
102 119 112 115 118 118 126
Inventories, net
20 22 23 25 25 26 26
Prepaid Expenses
20 24 21 21 25 22 24
Current Deferred & Refundable Income Taxes
18 18 18 18 18 18 17
Plant, Property, & Equipment, net
68 96 112 121 119 116 115
Total Noncurrent Assets
792 811 781 763 702 677 673
Goodwill
237 287 287 287 287 286 286
Intangible Assets
371 369 359 357 341 320 313
Other Noncurrent Operating Assets
119 125 129 120 74 71 74
Total Liabilities & Shareholders' Equity
1,212 1,169 1,187 1,149 1,111 1,085 1,081
Total Liabilities
295 334 452 466 351 345 350
Total Current Liabilities
129 143 221 209 146 149 154
Accounts Payable
30 37 40 34 33 33 30
Accrued Expenses
85 92 164 158 99 98 111
Other Current Liabilities
14 15 17 18 14 13 14
Total Noncurrent Liabilities
166 191 231 256 204 196 195
Long-Term Debt
- - 38 39 39 39 39
Noncurrent Deferred & Payable Income Tax Liabilities
38 33 33 32 31 31 31
Other Noncurrent Operating Liabilities
128 158 160 186 135 126 125
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
917 835 735 683 760 741 732
Total Preferred & Common Equity
917 835 735 683 760 741 732
Total Common Equity
917 835 735 683 760 741 732
Common Stock
1,252 1,264 1,278 1,287 1,420 1,437 1,446
Retained Earnings
-324 -421 -537 -598 -656 -692 -714
Accumulated Other Comprehensive Income / (Loss)
-11 -7.40 -5.40 -5.30 -4.20 -4.00 -0.10

Annual Metrics and Ratios for Myriad Genetics

This table displays calculated financial ratios and metrics derived from Myriad Genetics' official financial filings.

Metric 2022 2023 2024
Growth Metrics
- - -
Revenue Growth
-1.77% 11.03% 11.21%
EBITDA Growth
-852.59% -116.04% 67.55%
EBIT Growth
-173.44% -87.00% 53.25%
NOPAT Growth
26.19% -83.07% 52.02%
Net Income Growth
-311.76% -135.09% 51.65%
EPS Growth
-297.14% -128.78% 55.66%
Operating Cash Flow Growth
-671.51% -4.33% 92.16%
Free Cash Flow Firm Growth
-205.97% 40.75% 69.66%
Invested Capital Growth
25.63% -4.93% -6.24%
Revenue Q/Q Growth
2.57% 2.56% 1.70%
EBITDA Q/Q Growth
-11.07% 14.81% -12.92%
EBIT Q/Q Growth
-6.95% 7.13% -5.79%
NOPAT Q/Q Growth
-6.92% 7.48% -6.65%
Net Income Q/Q Growth
-44.89% 4.05% -9.74%
EPS Q/Q Growth
-47.87% 5.36% -10.16%
Operating Cash Flow Q/Q Growth
2.03% -74.65% 87.57%
Free Cash Flow Firm Q/Q Growth
-25.68% 16.23% 62.20%
Invested Capital Q/Q Growth
8.93% 7.11% -4.85%
Profitability Metrics
- - -
Gross Margin
70.22% 68.64% 69.89%
EBITDA Margin
-12.87% -25.04% -7.31%
Operating Margin
-20.73% -34.17% -14.74%
EBIT Margin
-20.64% -34.76% -14.61%
Profit (Net Income) Margin
-16.51% -34.96% -15.20%
Tax Burden Percent
79.66% 100.42% 103.08%
Interest Burden Percent
100.43% 100.15% 100.90%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-15.31% -25.80% -13.11%
ROIC Less NNEP Spread (ROIC-NNEP)
-10.52% 35.30% 36.35%
Return on Net Nonoperating Assets (RNNOA)
3.22% -5.75% -4.05%
Return on Equity (ROE)
-12.08% -31.55% -17.15%
Cash Return on Invested Capital (CROIC)
-38.03% -20.74% -6.66%
Operating Return on Assets (OROA)
-11.11% -22.33% -11.26%
Return on Assets (ROA)
-8.89% -22.45% -11.71%
Return on Common Equity (ROCE)
-12.08% -31.55% -17.15%
Return on Equity Simple (ROE_SIMPLE)
-12.64% -33.62% -18.16%
Net Operating Profit after Tax (NOPAT)
-98 -180 -86
NOPAT Margin
-14.51% -23.92% -10.32%
Net Nonoperating Expense Percent (NNEP)
-4.79% -61.10% -49.46%
Return On Investment Capital (ROIC_SIMPLE)
-11.11% -21.93% -11.67%
Cost of Revenue to Revenue
29.78% 31.36% 30.11%
SG&A Expenses to Revenue
36.54% 37.67% 32.94%
R&D to Revenue
12.59% 11.78% 13.54%
Operating Expenses to Revenue
90.95% 102.81% 84.63%
Earnings before Interest and Taxes (EBIT)
-140 -262 -122
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-87 -189 -61
Valuation Ratios
- - -
Price to Book Value (P/BV)
1.33 2.01 1.78
Price to Tangible Book Value (P/TBV)
5.36 10.75 8.19
Price to Revenue (P/Rev)
1.73 2.09 1.49
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.41 2.16 1.86
Enterprise Value to Revenue (EV/Rev)
1.48 1.95 1.42
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.05 0.06
Long-Term Debt to Equity
0.00 0.05 0.06
Financial Leverage
-0.31 -0.16 -0.11
Leverage Ratio
1.36 1.41 1.46
Compound Leverage Factor
1.37 1.41 1.48
Debt to Total Capital
0.00% 4.69% 5.35%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 4.69% 5.35%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 95.31% 94.65%
Debt to EBITDA
0.00 -0.20 -0.65
Net Debt to EBITDA
0.00 0.54 1.03
Long-Term Debt to EBITDA
0.00 -0.20 -0.65
Debt to NOPAT
0.00 -0.21 -0.46
Net Debt to NOPAT
0.00 0.57 0.73
Long-Term Debt to NOPAT
0.00 -0.21 -0.46
Altman Z-Score
2.15 1.90 1.84
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
2.00 2.01 1.82
Quick Ratio
1.58 1.64 1.36
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-245 -145 -44
Operating Cash Flow to CapEx
-234.66% -151.30% -29.29%
Free Cash Flow to Firm to Interest Expense
-76.41 -49.96 -15.70
Operating Cash Flow to Interest Expense
-33.22 -38.24 -3.11
Operating Cash Flow Less CapEx to Interest Expense
-47.38 -63.52 -13.71
Efficiency Ratios
- - -
Asset Turnover
0.54 0.64 0.77
Accounts Receivable Turnover
7.03 6.98 7.11
Inventory Turnover
11.41 11.22 10.19
Fixed Asset Turnover
10.69 7.44 7.09
Accounts Payable Turnover
6.92 8.65 8.68
Days Sales Outstanding (DSO)
51.89 52.31 51.31
Days Inventory Outstanding (DIO)
31.98 32.53 35.82
Days Payable Outstanding (DPO)
52.76 42.19 42.04
Cash Conversion Cycle (CCC)
31.11 42.65 45.09
Capital & Investment Metrics
- - -
Invested Capital
716 681 638
Invested Capital Turnover
1.06 1.08 1.27
Increase / (Decrease) in Invested Capital
146 -35 -43
Enterprise Value (EV)
1,006 1,471 1,185
Market Capitalization
1,176 1,573 1,248
Book Value per Share
$10.93 $9.53 $7.70
Tangible Book Value per Share
$2.71 $1.78 $1.67
Total Capital
886 822 741
Total Debt
0.00 39 40
Total Long-Term Debt
0.00 39 40
Net Debt
-170 -102 -63
Capital Expenditures (CapEx)
45 73 30
Debt-free, Cash-free Net Working Capital (DFCFNWC)
23 17 32
Debt-free Net Working Capital (DFNWC)
137 158 134
Net Working Capital (NWC)
137 158 134
Net Nonoperating Expense (NNE)
14 83 41
Net Nonoperating Obligations (NNO)
-170 -102 -63
Total Depreciation and Amortization (D&A)
53 73 61
Debt-free, Cash-free Net Working Capital to Revenue
3.32% 2.23% 3.76%
Debt-free Net Working Capital to Revenue
20.25% 20.94% 15.99%
Net Working Capital to Revenue
20.25% 20.94% 15.99%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($1.39) ($3.18) ($1.41)
Adjusted Weighted Average Basic Shares Outstanding
80.60M 82.80M 90.60M
Adjusted Diluted Earnings per Share
($1.39) ($3.18) ($1.41)
Adjusted Weighted Average Diluted Shares Outstanding
80.60M 82.80M 90.60M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
81.22M 89.87M 91.31M
Normalized Net Operating Profit after Tax (NOPAT)
-87 -180 -47
Normalized NOPAT Margin
-12.76% -23.92% -5.57%
Pre Tax Income Margin
-20.73% -34.81% -14.74%
Debt Service Ratios
- - -
EBIT to Interest Expense
-43.75 -90.28 -43.71
NOPAT to Interest Expense
-30.76 -62.13 -30.88
EBIT Less CapEx to Interest Expense
-57.91 -115.55 -54.32
NOPAT Less CapEx to Interest Expense
-44.91 -87.41 -41.48
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Myriad Genetics

This table displays calculated financial ratios and metrics derived from Myriad Genetics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
-6.52% 10.57% 9.88% 2.34% 22.70% 10.57% 11.59% 15.26% 11.15% 7.12%
EBITDA Growth
-157.19% -29.19% -165.08% -2,041.67% -48.73% 55.84% 69.16% 78.89% 88.87% -41.18%
EBIT Growth
-209.34% -21.11% -106.25% -555.93% -36.63% 38.51% 50.76% 68.30% 65.79% -20.87%
NOPAT Growth
36.22% -21.11% -103.91% -538.76% -33.56% 39.85% 46.55% 67.90% 66.72% -24.52%
Net Income Growth
-242.68% -456.58% -166.83% -723.40% -74.64% 26.24% 52.47% 68.39% 63.95% -36.22%
EPS Growth
-243.33% -642.86% -157.69% -688.89% -74.42% 34.62% 56.72% 71.13% 68.00% -38.24%
Operating Cash Flow Growth
92.88% 23.16% 28.60% 98.19% -689.29% -649.32% 43.98% 388.89% 103.17% 112.07%
Free Cash Flow Firm Growth
-136.52% -154.69% -171.45% 8.84% 84.87% 107.29% 108.02% 10.13% -142.72% 13.59%
Invested Capital Growth
18.47% 25.63% 18.86% -2.71% -3.32% -4.93% -4.37% 4.61% 5.54% -6.24%
Revenue Q/Q Growth
-12.77% 13.68% 1.91% 1.27% 4.58% 2.45% 2.85% 4.60% 0.85% -1.27%
EBITDA Q/Q Growth
-554.17% -22.61% 13.25% -207.78% 54.57% 63.60% 39.41% -110.68% 76.04% -361.54%
EBIT Q/Q Growth
-151.41% -17.30% -1.15% -119.89% 47.63% 47.20% 19.00% -41.54% 43.48% -86.54%
NOPAT Q/Q Growth
-152.81% -16.00% 0.00% -117.82% 47.14% 47.75% 11.15% -30.82% 45.21% -95.50%
Net Income Q/Q Growth
-148.94% -20.51% -29.31% -112.25% 47.20% 49.10% 16.67% -41.15% 39.78% -92.31%
EPS Q/Q Growth
-138.89% -20.93% -28.85% -111.94% 47.18% 54.67% 14.71% -41.38% 41.46% -95.83%
Operating Cash Flow Q/Q Growth
94.37% -160.71% -354.79% 97.29% -2,355.56% -147.51% 66.00% 113.98% -73.08% 842.86%
Free Cash Flow Firm Q/Q Growth
-98.34% -36.30% 16.92% 59.41% 67.09% 165.71% -8.63% -554.81% 11.11% 130.75%
Invested Capital Q/Q Growth
-0.96% 8.93% 1.40% -11.06% -1.58% 7.11% 2.00% -2.71% -0.71% -4.85%
Profitability Metrics
- - - - - - - - - -
Gross Margin
67.77% 69.69% 67.33% 68.50% 69.98% 68.67% 68.05% 69.55% 70.23% 71.65%
EBITDA Margin
-20.08% -21.65% -18.43% -56.02% -24.34% -8.65% -5.09% -10.26% -2.44% -11.40%
Operating Margin
-28.77% -29.36% -28.81% -61.96% -31.32% -15.97% -13.80% -17.26% -9.38% -18.57%
EBIT Margin
-28.45% -29.36% -29.14% -63.27% -31.68% -16.33% -12.86% -17.40% -9.75% -18.42%
Profit (Net Income) Margin
-22.44% -23.79% -30.19% -63.27% -31.94% -15.87% -12.86% -17.35% -10.36% -20.18%
Tax Burden Percent
79.41% 81.19% 103.99% 100.00% 100.16% 96.59% 100.39% 98.66% 104.25% 108.42%
Interest Burden Percent
99.33% 99.81% 99.62% 100.00% 100.66% 100.62% 99.62% 101.09% 101.92% 101.03%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-21.98% -21.68% -20.96% -46.29% -24.90% -12.06% -10.53% -14.67% -8.28% -16.50%
ROIC Less NNEP Spread (ROIC-NNEP)
-20.91% -19.65% -12.85% -26.72% -12.38% -5.28% -3.12% -0.22% 6.63% 1.81%
Return on Net Nonoperating Assets (RNNOA)
7.46% 6.02% 3.23% 5.92% 2.37% 0.86% 0.34% 0.02% -0.51% -0.20%
Return on Equity (ROE)
-14.51% -15.66% -17.73% -40.37% -22.53% -11.20% -10.19% -14.65% -8.78% -16.71%
Cash Return on Invested Capital (CROIC)
-32.10% -38.03% -34.74% -25.38% -26.75% -20.74% -18.51% -21.03% -17.80% -6.66%
Operating Return on Assets (OROA)
-14.77% -15.81% -16.70% -36.89% -19.71% -10.49% -8.73% -12.29% -7.20% -14.20%
Return on Assets (ROA)
-11.65% -12.81% -17.30% -36.89% -19.87% -10.19% -8.73% -12.25% -7.65% -15.55%
Return on Common Equity (ROCE)
-14.52% -15.66% -17.73% -40.37% -22.53% -11.20% -10.19% -14.65% -8.78% -16.71%
Return on Equity Simple (ROE_SIMPLE)
-8.43% 0.00% -17.50% -33.76% -40.15% 0.00% -30.87% -20.96% -15.85% 0.00%
Net Operating Profit after Tax (NOPAT)
-32 -37 -37 -80 -42 -22 -20 -26 -14 -27
NOPAT Margin
-20.14% -20.55% -20.17% -43.37% -21.92% -11.18% -9.66% -12.08% -6.56% -13.00%
Net Nonoperating Expense Percent (NNEP)
-1.07% -2.03% -8.10% -19.58% -12.53% -6.78% -7.41% -14.45% -14.90% -18.32%
Return On Investment Capital (ROIC_SIMPLE)
-3.44% -4.13% -4.38% -10.29% -5.83% -2.67% -2.45% -3.28% -1.82% -3.70%
Cost of Revenue to Revenue
32.23% 30.32% 32.67% 31.50% 30.02% 31.33% 31.95% 30.45% 29.77% 28.35%
SG&A Expenses to Revenue
83.44% -67.66% 83.72% 76.68% 70.92% -73.65% 69.54% 68.51% 65.21% -70.61%
R&D to Revenue
13.11% 13.16% 12.42% 11.55% 12.51% 10.68% 12.31% 12.81% 13.36% 15.62%
Operating Expenses to Revenue
96.55% 99.04% 96.14% 130.46% 101.30% 84.64% 81.85% 86.81% 79.61% 90.22%
Earnings before Interest and Taxes (EBIT)
-45 -52 -53 -116 -61 -32 -26 -37 -21 -39
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-31 -39 -33 -103 -47 -17 -10 -22 -5.20 -24
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
1.68 1.33 2.26 2.57 1.92 2.01 2.31 2.99 3.40 1.78
Price to Tangible Book Value (P/TBV)
4.97 5.36 10.56 21.19 32.67 10.75 13.27 16.44 18.72 8.19
Price to Revenue (P/Rev)
2.33 1.73 2.72 2.70 1.79 2.09 2.26 2.76 3.02 1.49
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.95 1.41 2.45 2.79 1.99 2.16 2.43 3.19 3.62 1.86
Enterprise Value to Revenue (EV/Rev)
1.93 1.48 2.56 2.58 1.72 1.95 2.18 2.69 2.95 1.42
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.05 0.06 0.05 0.05 0.05 0.05 0.06
Long-Term Debt to Equity
0.00 0.00 0.00 0.05 0.06 0.05 0.05 0.05 0.05 0.06
Financial Leverage
-0.36 -0.31 -0.25 -0.22 -0.19 -0.16 -0.11 -0.10 -0.08 -0.11
Leverage Ratio
1.35 1.36 1.36 1.42 1.48 1.41 1.43 1.54 1.58 1.46
Compound Leverage Factor
1.34 1.36 1.35 1.42 1.49 1.41 1.42 1.56 1.61 1.48
Debt to Total Capital
0.00% 0.00% 0.00% 4.96% 5.33% 4.69% 4.85% 4.98% 5.06% 5.35%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 4.96% 5.33% 4.69% 4.85% 4.98% 5.06% 5.35%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 95.04% 94.67% 95.31% 95.15% 95.02% 94.94% 94.65%
Debt to EBITDA
0.00 0.00 0.00 -0.19 -0.17 -0.20 -0.22 -0.41 -0.72 -0.65
Net Debt to EBITDA
0.00 0.00 0.00 0.43 0.22 0.54 0.37 0.61 1.12 1.03
Long-Term Debt to EBITDA
0.00 0.00 0.00 -0.19 -0.17 -0.20 -0.22 -0.41 -0.72 -0.65
Debt to NOPAT
0.00 0.00 0.00 -0.21 -0.20 -0.21 -0.24 -0.36 -0.48 -0.46
Net Debt to NOPAT
0.00 0.00 0.00 0.49 0.25 0.57 0.40 0.54 0.75 0.73
Long-Term Debt to NOPAT
0.00 0.00 0.00 -0.21 -0.20 -0.21 -0.24 -0.36 -0.48 -0.46
Altman Z-Score
3.40 2.39 3.45 2.22 1.49 2.56 2.95 3.75 4.20 2.11
Noncontrolling Interest Sharing Ratio
-0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
2.73 2.00 1.83 1.33 1.27 2.01 1.99 1.96 1.90 1.82
Quick Ratio
2.29 1.58 1.38 1.06 0.96 1.64 1.52 1.44 1.46 1.36
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-134 -183 -152 -62 -20 13 12 -55 -49 15
Operating Cash Flow to CapEx
-15.82% -50.00% -141.28% -4.79% -126.29% -405.19% -216.28% 29.21% 11.11% 111.86%
Free Cash Flow to Firm to Interest Expense
-167.50 -202.93 -303.48 -123.18 -20.27 14.80 24.34 -69.19 -61.50 21.61
Operating Cash Flow to Interest Expense
-3.50 -8.11 -66.40 -1.80 -22.10 -60.78 -37.20 3.25 0.88 9.43
Operating Cash Flow Less CapEx to Interest Expense
-25.63 -24.33 -113.40 -39.40 -39.60 -75.78 -54.40 -7.88 -7.00 1.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.52 0.54 0.57 0.58 0.62 0.64 0.68 0.71 0.74 0.77
Accounts Receivable Turnover
6.76 7.03 6.29 6.31 6.76 6.98 6.53 6.99 6.84 7.11
Inventory Turnover
10.15 11.41 11.40 11.68 10.22 11.22 10.41 10.21 9.91 10.19
Fixed Asset Turnover
11.93 10.69 9.78 8.48 7.80 7.44 7.21 7.03 6.98 7.09
Accounts Payable Turnover
8.56 6.92 6.70 7.20 7.20 8.65 6.94 6.79 8.00 8.68
Days Sales Outstanding (DSO)
54.03 51.89 58.00 57.84 54.02 52.31 55.91 52.21 53.38 51.31
Days Inventory Outstanding (DIO)
35.95 31.98 32.01 31.26 35.70 32.53 35.05 35.74 36.84 35.82
Days Payable Outstanding (DPO)
42.64 52.76 54.44 50.72 50.72 42.19 52.57 53.75 45.61 42.04
Cash Conversion Cycle (CCC)
47.34 31.11 35.58 38.38 39.01 42.65 38.39 34.20 44.62 45.09
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
657 716 726 646 636 681 694 676 671 638
Invested Capital Turnover
1.09 1.06 1.04 1.07 1.14 1.08 1.09 1.21 1.26 1.27
Increase / (Decrease) in Invested Capital
103 146 115 -18 -22 -35 -32 30 35 -43
Enterprise Value (EV)
1,279 1,006 1,778 1,801 1,266 1,471 1,687 2,155 2,427 1,185
Market Capitalization
1,539 1,176 1,887 1,890 1,313 1,573 1,752 2,214 2,488 1,248
Book Value per Share
$11.37 $10.93 $10.28 $9.01 $8.35 $9.53 $8.45 $8.18 $8.06 $7.70
Tangible Book Value per Share
$3.84 $2.71 $2.20 $1.09 $0.49 $1.78 $1.47 $1.49 $1.46 $1.67
Total Capital
917 886 835 774 722 822 799 779 771 741
Total Debt
0.00 0.00 0.00 38 39 39 39 39 39 40
Total Long-Term Debt
0.00 0.00 0.00 38 39 39 39 39 39 40
Net Debt
-259 -170 -109 -89 -48 -102 -66 -59 -61 -63
Capital Expenditures (CapEx)
18 15 24 19 18 14 8.60 8.90 6.30 5.90
Debt-free, Cash-free Net Working Capital (DFCFNWC)
30 23 40 -48 -30 17 40 45 39 32
Debt-free Net Working Capital (DFNWC)
223 137 118 73 56 158 144 143 139 134
Net Working Capital (NWC)
223 137 118 73 56 158 144 143 139 134
Net Nonoperating Expense (NNE)
3.60 5.76 18 37 19 9.22 6.47 11 8.10 15
Net Nonoperating Obligations (NNO)
-259 -170 -109 -89 -48 -102 -66 -65 -61 -63
Total Depreciation and Amortization (D&A)
13 14 19 13 14 15 16 15 16 15
Debt-free, Cash-free Net Working Capital to Revenue
4.54% 3.32% 5.70% -6.93% -4.11% 2.23% 5.15% 5.66% 4.74% 3.76%
Debt-free Net Working Capital to Revenue
33.75% 20.25% 17.03% 10.47% 7.64% 20.94% 18.63% 17.79% 16.87% 15.99%
Net Working Capital to Revenue
33.75% 20.25% 17.03% 10.47% 7.64% 20.94% 18.63% 17.79% 16.87% 15.99%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.43) ($0.52) ($0.67) ($1.42) ($0.75) ($0.34) ($0.29) ($0.41) ($0.24) ($0.47)
Adjusted Weighted Average Basic Shares Outstanding
80.70M 80.60M 81.30M 81.70M 81.90M 82.80M 89.90M 90.60M 90.90M 90.60M
Adjusted Diluted Earnings per Share
($0.43) ($0.52) ($0.67) ($1.42) ($0.75) ($0.34) ($0.29) ($0.41) ($0.24) ($0.47)
Adjusted Weighted Average Diluted Shares Outstanding
80.70M 80.60M 81.30M 81.70M 81.90M 82.80M 89.90M 90.60M 90.90M 90.60M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
81.03M 81.22M 81.56M 81.88M 82.20M 89.87M 90.51M 90.82M 91.04M 91.31M
Normalized Net Operating Profit after Tax (NOPAT)
-32 -32 -37 -25 -18 -22 -20 -17 -12 -27
Normalized NOPAT Margin
-20.14% -18.11% -20.17% -13.81% -9.41% -11.18% -9.66% -8.24% -5.84% -13.00%
Pre Tax Income Margin
-28.26% -29.30% -29.03% -63.27% -31.89% -16.43% -12.81% -17.59% -9.94% -18.61%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-55.63 -58.00 -105.60 -232.20 -60.80 -35.67 -52.00 -46.00 -26.00 -55.43
NOPAT to Interest Expense
-39.38 -40.60 -73.08 -159.18 -42.07 -24.42 -39.06 -31.94 -17.50 -39.10
EBIT Less CapEx to Interest Expense
-77.75 -74.22 -152.60 -269.80 -78.30 -50.67 -69.20 -57.13 -33.88 -63.86
NOPAT Less CapEx to Interest Expense
-61.50 -56.82 -120.08 -196.78 -59.57 -39.42 -56.26 -43.06 -25.38 -47.53
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Myriad Genetics' Financials

When does Myriad Genetics's financial year end?

According to the most recent income statement we have on file, Myriad Genetics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Myriad Genetics' net income changed over the last 2 years?

Myriad Genetics' net income appears to be on an upward trend, with a most recent value of -$127.30 million in 2024, rising from -$112 million in 2022. The previous period was -$263.30 million in 2023.

What is Myriad Genetics's operating income?
Myriad Genetics's total operating income in 2024 was -$123.50 million, based on the following breakdown:
  • Total Gross Profit: $585.40 million
  • Total Operating Expenses: $708.90 million
How has Myriad Genetics revenue changed over the last 2 years?

Over the last 2 years, Myriad Genetics' total revenue changed from $678.40 million in 2022 to $837.60 million in 2024, a change of 23.5%.

How much debt does Myriad Genetics have?

Myriad Genetics' total liabilities were at $326.50 million at the end of 2024, a 10.1% decrease from 2023, and a 4.3% increase since 2022.

How much cash does Myriad Genetics have?

In the past 2 years, Myriad Genetics' cash and equivalents has ranged from $56.90 million in 2022 to $132.10 million in 2023, and is currently $102.40 million as of their latest financial filing in 2024.

How has Myriad Genetics' book value per share changed over the last 2 years?

Over the last 2 years, Myriad Genetics' book value per share changed from 10.93 in 2022 to 7.70 in 2024, a change of -29.5%.

Remove Ads


This page (NASDAQ:MYGN) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners